ng28ÄϹ¬

ÌõÄ¿µÄ

ng28ÄϹ¬µÚÆß´ÎÈëѡȫÇò¿ÉÁ¬ÐøÆóÒµ°ÙÇ¿

2023Äê1ÔÂ18ÈÕ £¬¼ÓÄôóÖªÃûýÌåºÍͶ×ÊÑо¿¹«Ë¾Corporate KnightsÐû²¼2023¡°È«Çò¿ÉÁ¬ÐøÉú³¤ÆóÒµ°ÙÇ¿¡± £¨2023 Global 100 Most Sustainable Corporations in the World£©¡£ng28ÄϹ¬Öêʽ»áÉçλÁеÚ53λ £¬ÊÇÈ«ÇòÅÅÃû×î¸ßµÄÖÆÒ©ÆóÒµ¡£ÕâÊÇÒ²ng28ÄϹ¬µÚÆß´Î½øÈë°ÙÇ¿Ãûµ¥¡£

FDAÔÚ¿ìËÙͨµÀÈ϶¨ÏÂÅú×¼LEQEMBI?£¨lecanemab-irmb£©ÓÃÓÚÖÎÁư¢¶û´Äº£Ä¬²¡

¼ÓËÙÉóÆÀÊÇ»ùÓÚIIÆÚÊý¾Ý £¬¸ÃÊý¾ÝÏÔʾÔÚ½ÓÊÜLEQEMBI?ÖÎÁƵÄÔçÆÚAD»¼ÕßÖеí·ÛÑù¦Â°ß¿éµÄ¼õÉÙ¡£
LEQEMBIµÄÖÎÁÆÓ¦¿ªÊ¼ÓÚÇá¶ÈÈÏÖªÕϰ­»òÇá¶È³Õ´ô½×¶ÎµÄ»¼Õß £¬¼´ÔÚÁÙ´²ÊÔÑéÖпªÊ¼ÖÎÁƵÄÈËȺ¡£

ng28ÄϹ¬ÔÚÖйúµÝ½»°¢¶û´Äº£Ä¬²¡ÖÎÁÆÒ©ÎïÂØ¿¨Ä¹ÉÏÊÐÉêÇë

ng28ÄϹ¬ºÍ²³½¡Ðû²¼ £¬ng28ÄϹ¬ÒÑÏòÖйú¹ú¼ÒÒ©Æ·¼à¶½ÖÎÀí¾ÖÌá½»ÂØ¿¨Ä¹£¨lecanemab £¬¿ª·¢´úºÅ: BAN2401£©ÉÏÊÐÉêÇë £¬ÂØ¿¨Ä¹Êǰ¢¶û´Äº£Ä¬²¡£¨AD£©ËùÖÂÇá¶ÈÈÏÖªÕϰ­£¨MCI£©ºÍÇá¶ÈAD(ͳ³ÆÎªÔçÆÚAD)µÄ¿¹µí·ÛÑùÂÑ°× (A¦Â) Ô­ÏËά¿¹Ìå¡£

°²Ë¹Ì©À´¡¢ÎäÌï¡¢µÚÒ»Èý¹²ºÍng28ÄϹ¬½«ÅäºÏ¼õÉÙÓÉÒ©Æ·°ü×°Ëùµ¼ÖµÄÇé¿öµ£¸º

12ÔÂ22ÈÕ £¬°²Ë¹Ì©À´ÖÆÒ©¡¢µÚÒ»Èý¹²Öêʽ»áÉç¡¢ÎäÌïÖÆÒ©Öêʽ»áÉçºÍng28ÄϹ¬Öêʽ»áÉçÅäºÏÐû²¼ £¬Ëļҹ«Ë¾ÒѸ濢ÏàÖú £¬½«ÅäºÏ¼õÉÙÓÉÒ©Æ·°ü×°Ëùµ¼ÖµÄÇé¿öµ£¸º¡£

ng28ÄϹ¬½«×ªÈÿ¹ñ²ðïÒ©ÎïFycompa? CIIIÔÚÃÀÉÌҵȨÀûתÈøøCatalystÖÆÒ©¹«Ë¾

12ÔÂ20ÈÕ £¬ng28ÄϹ¬ÓëCatalystÖÆÒ©¹«Ë¾¸æ¿¢Ð­Òé £¬½«ng28ÄϹ¬¿¹ñ²ðïÒ©ÎïFycompa? CIIIÔÚÃÀ¹úµÄÉÌҵȨÀûתÈøøCatalystÖÆÒ©¹«Ë¾ £¬²¢ÎªÆäÌṩng28ÄϹ¬ñ²ðï¹ÜÏß²úÆ·¶À¼Ò̸ÅÐÆÚ¡£ng28ÄϹ¬½«ÔÚÃÀ¹úÒÔÍâµÄ¹ú¼ÒºÍµØÇø¼á³ÖÆä¶ÔFycompa?µÄÉÌҵȨÀû £¬²¢¼ÌÐøÎªñ²ðﻼÕß×ö³öТ¾´¡£Í걾Ǯ´ÎתÈÃÈ¡¾öÓÚͨ¹ýÃÀ¹ú·´Â¢¶Ï·¨µÄÏà¹ØÉó²é¡£

ng28ÄϹ¬Óëʥ·Ò×˹»ªÊ¢¶Ù´óѧҽѧԺ´ïÓñ³ÉÃæÑо¿ÏàÖúЭÒé £¬ÎªÉñ¾­ÍËÐÐÐÔ¼²²¡´´Á¢ÐµÄÖÎÁÆÒªÁì

12ÔÂ15ÈÕ £¬ng28ÄϹ¬Ó뻪ʢ¶Ù´óѧʥ·Ò×˹ҽѧԺ¸æ¿¢ÁËÒ»ÏîÈ«ÃæµÄÑо¿ÏàÖúЭÒé £¬Ö¼ÔÚΪ°üÀ¨°¢¶û´Äº£Ä¬²¡£¨AD£©ºÍÅÁ½ðÉ­²¡£¨PD£©ÔÚÄÚµÄÉñ¾­ÍËÐÐÐÔ¼²²¡´´Á¢Ç±ÔÚµÄÐÂÐÍÖÎÁÆÒªÁì¡£

ng28ÄϹ¬½«ÔÚ2022ÄêÊ¥°²¶«Äá°ÂÈéÏÙ°©ÑÐÌÖ»áÉϽéÉܰ¬Á¢²¼ÁÖµÄÏà¹ØÑо¿

ng28ÄϹ¬Öêʽ»áÉç12ÔÂ1ÈÕÌåÏÖ £¬½«ÔÚ12ÔÂ6ÈÕÖÁ10ÈÕÓÚÃÀ¹úµÂ¿ËÈøË¹ÖÝÊ¥°²¶«Äá°Â¾ÙÐеÄ2022ÄêÊ¥°²¶«Äá°ÂÈéÏÙ°©ÑÐÌÖ»á (SABCS)ÉÏÐû²¼Æä×ÔÖ÷Ñз¢µÄ¿¹°©Ò©Îï¼×»ÇËá°¬Á¢²¼ÁÖ£¨HALAVEN?£©µÄ×îÐÂÑо¿½á¹û¡£

ng28ÄϹ¬ÔÚ°¢¶û´Äº£Ä¬²¡ÁÙ´²ÊÔÑ飨CTAD£©¼¯»áÉÏÐû²¼ÁËÂØ¿¨Ä¹ÑéÖ¤ÐÔIIIÆÚClarity-ADÑо¿¶ÔÔçÆÚ°¢¶û´Äº£Ä¬Ö¢µÄÈ«²¿½á¹û

ng28ÄϹ¬ºÍ²³½¡½ñÈÕÐû²¼ £¬ÔÚ¼ÓÖݾɽðɽ¾ÙÐеÄ2022Äê°¢¶û´Äº£Ä¬²¡ÁÙ´²ÊÔÑ飨CTAD£©¼¯»áÉÏ £¬ng28ÄϹ¬½«Ðû²¼ÂØ¿¨Ä¹£¨¿ª·¢´úÂ룺BAN2401£©´óÐÍÈ«ÇòIIIÆÚÑéÖ¤ÐÔClarity ADÁÙ´²Ñо¿µÄ½á¹û £¬ÊÔÑéÒ©ÎïÂØ¿¨Ä¹ÊÇÖÎÁÆÄÔÄÚÈ·Èϱ£´æµí·ÛÑùÂѰײ¡ÀíµÄ°¢¶û´Äº£Ä¬²¡£¨AD£©ËùÖÂÇá¶ÈÈÏÖªÕϰ­£¨MCI£©ºÍÇá¶ÈAD(ͳ³ÆÎªÔçÆÚAD)µÄ¿¹µí·ÛÑùÂÑ°× (A¦Â) Ô­ÏËά¿¹Ìå¡£

ng28ÄϹ¬½«ÔÚµÚ15½ì°¢¶û´Äº£Ä¬²¡ÁÙ´²ÊÔÑ飨CTAD£©¼¯»áÉÏÕ¹Ê¾ÂØ¿¨Ä¹LECANEMABÑéÖ¤ÐÔIIIÆÚÁÙ´²ÊÔÑ飨Clarity AD£©ºÍÆäËû°¢¶û´Äº£Ä¬²¡Ñо¿µÄÈ«²¿½á¹û

ng28ÄϹ¬Öêʽ»áÉ罫ÔÚµÚ15½ì°¢¶û´Äº£Ä¬²¡ÁÙ´²ÊÔÑ飨CTAD£©¼¯»áÉϽéÉÜÂØ¿¨Ä¹£¨lecanemab £¬¿ª·¢´úÂ룺BAN2401£©Clarity AD IIIÆÚÑéÖ¤ÐÔÁÙ´²ÊÔÑéµÄÁÆÐ§¡¢Äþ¾²ÐÔºÍÉúÎï±ê¼ÇÎï½á¹û £¬ÊÔÑéÒ©ÎïÂØ¿¨Ä¹ÊÇÖÎÁÆÄÔÄÚÈ·Èϱ£´æµí·ÛÑùÂѰײ¡ÀíµÄ°¢¶û´Äº£Ä¬²¡£¨AD£©ËùÖÂÇá¶ÈÈÏÖªÕϰ­£¨MCI£©ºÍÇá¶ÈAD(ͳ³ÆÎªÔçÆÚAD)µÄ¿¹µí·ÛÑùÂÑ°× (A¦Â) Ô­ÏËά¿¹Ìå¡£¼¯»á½«ÓÚ11ÔÂ29ÈÕÖÁ12ÔÂ2ÈÕÔÚ¼ÓÖݾɽðɽ¾ÙÐÐ £¬ng28ÄϹ¬ºÍÏà¹ØÑо¿ÈËÔ±½«ÔÚ¼¯»áµÚÒ»ÌìµÄ¿ÆÑ§¼¯»áÉÏչʾȫ²¿Êý¾Ý£¨11ÔÂ29ÈÕÏÂÎç4:50 PT£©¡£±ðµÄ £¬À´×ÔÂØ¿¨Ä¹ÁÙ´²¿ª·¢ÏîÄ¿ºÍng28ÄϹ¬AD¹ÜÏߵįäËüÖØÒªÑо¿ £¬°üÀ¨¸Ã¹«Ë¾ÕýÔÚÑо¿µÄ¿¹Î¢¹Ü½áºÏÇø£¨MTBR£©tau¿¹Ì壨E2814£© £¬½«Í¨¹ýËĸöÑݽ²Õ¹Ê¾ºÍÊ®¸öº£±¨Õ¹Ê¾½øÐнéÉÜ¡£

ng28ÄϹ¬¿¹ñ²ðïÒ© INOVELON? Âú×ãÈ«°¸ÀýÑо¿ÒªÇó

11ÔÂ2ÈÕ £¬ÈÕ±¾ºñÉúÀͶ¯Ê¡£¨MHLW£©½â³ýÁËng28ÄϹ¬¿¹ñ²ðïÒ©INOVELON?Ƭ¼Á100mgºÍ200mg£¨Í¨ÓÃÃû£ºrufinamide£©×÷ΪÆäËû¿¹ñ²ðïÒ©ÎAED£©µÄ¸¨ÖúÁÆ·¨ÓÃÓÚÖÎÁÆÂ×ŵ¿Ë˹-¼Ó˹ÍÐ×ÛºÏÕ÷£¨LSG£©Åú¼þÖÐËùÐèµÄÉÏÊкóÊÓ²ìÐÔÑо¿ £¬¼´È«°¸ÀýÑо¿µÄÒªÇó¡£

ÍøÕ¾µØÍ¼